U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157956) titled 'CVL006 Combination Therapy in Advanced Solid Tumors' on Aug. 22.
Brief Summary: This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.
Study Start Date: Sept. 10
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: CVL006 combined with pemetrexed and carboplatin
CVL006 combined with pemetrexed and carboplatin
DRUG: CVL006 in combi...